

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wayne GODFREY *et al.*

Group Art Unit: To Be Assigned

Appln. No.: To Be Assigned

Examiner: To Be Assigned

Filed: January 23, 2004

Atty. Docket: 16524.015

For: **Receptor on the Surface of Activated
T-Cells: ACT-4**

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the references listed on the attached Form PTO-1449. Copies of the listed references were previously cited by or submitted to, the Office in prior application Serial No. 09/852,845. Pursuant to 37 C.F.R. §1.98(d) and MPEP §609, the above-captioned application relies on this prior application for an earlier filing date under 35 U.S.C. §120.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

CERTIFICATION AND/OR FEE

Because this Information Disclosure Statement is being submitted before the mailing of a first Office action, no certification or fee is required.

Respectfully submitted,



David R. Marsh (Reg. Attorney No. 41,408)

Kristan L. Lansbery (Reg. Agent No. 53,183)

Date: January 23, 2004

ARNOLD & PORTER

555 Twelfth Street, N.W.

Washington, D.C. 20004-1206

(202) 942-5000 telephone

(202) 942-5999 facsimile

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	16524.015	To Be Assigned
	APPLICANTS Wayne GODFREY <i>et al.</i>	
	FILING DATE	GROUP
	January 23, 2004	To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,457,035	10/1995	Baum <i>et al.</i>			
	AB1	5,585,089	12/1996	Queen <i>et al.</i>			
	AC1	5,821,332	10/1998	Godfrey <i>et al.</i>			
	AD1	6,277,962	8/2001	Godfrey <i>et al.</i>			

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AE1	WO 96/15076	12/1990	PCT			Yes No
	AF1	WO 92/11870	07/1992	PCT			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AG	1	Abaza <i>et al.</i> , "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin", <i>Journal of Protein Chemistry</i> , 11(5):433-444 (1992)
	AH	1	Aversa <i>et al.</i> , "Activation panel antigen expression on PBL activated by PHA or in MLR", <i>Leukocyte Typing IV. White Cell Differentiation Antigens</i> (e.d. W. Knapp, Oxford U. Press, 1989) pp. 498-501
	AI	1	Bazan, "Emerging families of cytokines and receptors," <i>Current Biology</i> 3(9):603-606 (1993)
	AJ	1	Bird <i>et al.</i> , "Single-chain antigen-binding proteins", <i>Science</i> , 242(4877):423-426 (1988); Erratum in: <i>Science</i> , 244(4903):409, (1989)
	AK	1	Bowie <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 247:1306-1310 (1990)
	AL	1	Colman <i>et al.</i> , "Effects of amino acid sequence changes on antibody-antigen interactions", <i>Research in Immunology</i> , 145(1):33-36 (1994)
	AM	1	Dörken <i>et al.</i> , " <i>Leukocyte Typing IV. White cell differentiation antigens</i> " (ed. W. Knapp, Oxford U. Press, 1989) pp. 391, 396, 398, 409, 461, 474, 475, 477, 482, 485, 487, 488, 496, 501, 504, 1112, 1113, 1120, 1125, 1131, 1135

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.98(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO.	APPLICATION NO.
			16524.015	To Be Assigned
			APPLICANTS	
			Wayne GODFREY <i>et al.</i>	
			FILING DATE	GROUP
			January 23, 2004	To Be Assigned
	AA	2	Dunlap <i>et al.</i> , "Expression of activation antigens on HTLV-I and HTLV-II cell lines", <i>Leucocyte Typing IV. White Cell Differentiation Antigens</i> (Eds. W. Knapp at Oxford Univ. Press 1989) pp. 487-488	
	AB	2	Flanagan <i>et al.</i> , "The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts", <i>Cell</i> , 63:185-94 (1990)	
	AC	2	Godfrey <i>et al.</i> , "Stan-40, a new member of the FAS-TNFr superfamily expressed selectively on activated, human CD4+ T cells", <i>Journal of Cellular Biochemistry, Supplement</i> , O(18D):355 (1994)	
	AD	2	Godfrey <i>et al.</i> "Identification of a human OX-40- ligand, a costimulator of CD4+T cells with homology to tumor necrosis factor", <i>The Journal of Experimental Medicine</i> , 180(2):757-62 (1994)	
	AE	2	Godfrey <i>et al.</i> , "Molecular cloning of a cDNA encoding the human homolog of the rat OX-40 antigen," <i>Tissue Antigens</i> Abst. 42(4):253 (October 1993)	
	AF	2	Hamilton-Dutoit <i>et al.</i> , "An immunohistological analysis of the mAb in the activation antigen panel", <i>Leucocyte Typing IV. White Cell Differentiation Antigens</i> , (Eds. W. Knapp at Oxford Univ. Press 1989) pp. 475-476	
	AG	2	King <i>et al.</i> "Tonsillar dendritic-cell-induced T-lymphocyte proliferation: analysis of molecular mechanisms using the activation panel of mAb", <i>Leukocyte Typing IV. White Cell Differentiation Antigens</i> (e.d. W. Knapp, Oxford U. Press, 1989) pp. 503-505	
	AH	2	Knapp <i>et al.</i> , "Leukocyte Typing IV White Cell Differentiation Antigens" (Oxford University Press 1989) pp. 391, 396, 398, 409, 461, 474, 475, 477, 482, 485, 486, 487, 488, 496, 498, 499, 500, 501, 504, 1112, 1113, 1120, 1125, 1131, 1135	
	AI	2	Latza <i>et al.</i> , "The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen", <i>European Journal of Immunology</i> , 24(3):677-83 (1994)	
	AJ	2	Lederman <i>et al.</i> , "A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4", <i>Molecular Immunology</i> , 28(11):1171-1181 (1991)	
	AK	2	Li <i>et al.</i> , "β-Endorphin omission analogs: Dissociation of immunoreactivity from other biological activities", <i>PNAS</i> , 77(6):3211-3214 (1980)	
	AL	2	Marston, "The purification of eukaryotic polypeptides synthesized in <i>Escherichia coli</i> ", <i>Biochem. J.</i> , 240:1-12 (1986)	
EXAMINER				DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.98(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.				

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO.	APPLICATION NO.
			16524.015	To Be Assigned
			APPLICANTS Wayne GODFREY <i>et al.</i>	
			FILING DATE	GROUP
			January 23, 2004	To Be Assigned
	AA	3	Mallet <i>et al.</i> , "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor," <i>EMBO J.</i> 9(4):1063-1068 (1990)	
	AB	3	Mallet <i>et al.</i> , "A new superfamily of cell surface proteins related to the nerve growth factor receptor," <i>Immunology Today</i> 12:220-222 (1990)	
	AC	3	Mehra <i>et al.</i> , "Efficient mapping of protein antigenic determinants", <i>PNAS USA</i> , 83:7013-7 (1986)	
	AD	3	Miura <i>et al.</i> , "Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40 ^{tax} ," <i>Mol. and Cell. Biol.</i> 11(3):1313-1325 (1991)	
	AE	3	Ngo <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , pp. 433 and 492-495 (1994)	
	AF	3	Owens <i>et al.</i> , "The genetic engineering of monoclonal antibodies", <i>J. Immunol. Methods</i> , 168(2):149-165 (1994)	
	AG	3	Picker <i>et al.</i> , "Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selection on T cells during the virgin to memory cell transition," <i>J. of Immunology</i> 150(3):1105-1121 (1993)	
	AH	3	Picker <i>et al.</i> , "Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells," <i>J. of Immunology</i> 150(3):1122-1136 (1993)	
	AI	3	Queen <i>et al.</i> , "A humanized antibody that binds to the interleukin 2 receptor", <i>PNAS USA</i> , 86:10029-10033 (1989)	
	AJ	3	Rentrop <i>et al.</i> , "Biochemical analysis of the Workshop antibodies of the Activation Section", <i>Leukocyte Typing IV. White Cell Differentiation Antigens</i> (e.d. W. Knapp, Oxford U. Press, 1989) p. 473-474	
	AK	3	Tanaka <i>et al.</i> , "A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I)," <i>Int. J. Cancer</i> 36:549-555 (1985)	
	AL	3	The Merck Manual, 16 th Ed., Pages 346-354 (1992)	
EXAMINER				DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				
Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.98(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.				

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO.	APPLICATION NO.
			16524.015	To Be Assigned
			APPLICANTS	
			Wayne GODFREY <i>et al.</i>	
			FILING DATE	GROUP
			January 23, 2004	To Be Assigned
	AB	4	Thorpe <i>et al.</i> , "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates", <i>Immunological Review</i> , 62:119-158 (1982)	
	AC	4	Tozawa <i>et al.</i> , "Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I)," <i>Int. J. Cancer</i> 41:231-238 (1988)	
	AD	4	Vilella <i>et al.</i> , "Sequential appearance of the activation antigens", <i>Leukocyte Typing IV. White Cell Differentiation Antigens</i> (e.d. W. Knapp, Oxford U. Press, 1989) pp. 495-498	
	AE	4	Waugh <i>et al.</i> , "Staining of normal or rejecting kidney using the activation panel", <i>Leukocyte Typing IV. White Cell Differentiation Antigens</i> (e.d. W. Knapp, Oxford U. Press, 1989) pp. 485-486	
	AF	4	Young <i>et al.</i> , "Efficient isolation of genes by using antibody probes", <i>PNAS USA</i> , 80:1194-8 (1983)	
	AG	4		
	AH	4		
	AI	4		
	AJ	4		
	AK	4		
	AL	4		
	AM	4		
EXAMINER				DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				
Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.98(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.				